Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222346 | 0.87 | PTGDR2 (0.41) | TSHRPTGDR2SLC6A3 | |
| SCHEMBL2062415 | 0.87 | PTGDR2 (0.41) | TSHRPTGDR2SLC6A3 | |
| SCHEMBL2062805 | 0.87 | PTGDR2 (0.41) | TSHRPTGDR2SLC6A3 | |
| SCHEMBL11467456 | 0.86 | PTGDR2 (0.43) | TSHRPTGDR2SLC6A3 | |
| SCHEMBL11163642 | 0.76 | GABRA1 (0.55) | TSHR | |
| SCHEMBL15253060 | 0.76 | FEN1 (0.40) | TSHRPTGDR2 | |
| SCHEMBL4618238 | 0.74 | PTGDR2 (0.41) | PTGDR2 | |
| SCHEMBL9135944 | 0.74 | FEN1 (0.41) | TSHRPTGDR2 | |
| SCHEMBL25188997 | 0.73 | SLC6A2 (0.43) | TSHRPTGDR2SLC6A3 | |
| SCHEMBL290175 | 0.72 | TSHR (0.45) | TSHRPTGDR2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364479-A1 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | US | disclosed |
| US-8846954-B2 | Crystallisation and purification of glycopyrronium bromide | SOSEI R&D LTD. (GB) | 2014-09-30 | — | — | US | disclosed |
| EP-2580194-A1 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE | Chiesi Farmaceutici S.p.A. (IT) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011157536-A1 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-22 | — | — | WO | disclosed |
| US-20110306650-A1 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-15 | — | — | US | disclosed |
| US-7915303-B2 | Glycopyrronium salts and their therapeutic use | SOSEI R&D LTD. (GB) | 2011-03-29 | — | — | US | disclosed |
| EP-1856041-B1 | CRYSTALLISATION AND PURIFICATION OF GLYCOPYRRONIUM BROMIDE | SOSEI R & D LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-20090062372-A1 | Glycopyrronium Salts and Their Therapeutic Use | HEPTARES THERAPEUTICS LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20080227988-A1 | Reaction of glycopyrronium base with methyl bromide in solvent selected such that diastereoisomeric ratio of product favors R, S and S, R diastereoisomers over R, R, and S, S diastereoisomers, and separating desired diastereoisomers by controlled crystallisation steps; narrow particle size distribution | HEPTARES THERAPEUTICS LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| EP-1861361-A1 | GLYCOPYRRONIUM SALTS AND THEIR THERAPEUTIC USE | Sosei R&D Ltd. (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1856041-A1 | CRYSTALLISATION AND PURIFICATION OF GLYCOPYRRONIUM BROMIDE | Sosei R&D Ltd. (GB) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006100453-A1 | GLYCOPYRRONIUM SALTS AND THEIR THERAPEUTIC USE | SOSEI R & D LTD. (GB) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006092617-A1 | CRYSTALLISATION AND PURIFICATION OF GLYCOPYRRONIUM BROMIDE | SOSEI R & D LTD. (GB) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227988-A1 | Reaction of glycopyrronium base with methyl bromide in solvent selected such that diastereoisomeric ratio of product favors R, S and S, R diastereoisomers over R, R, and S, S diastereoisomers, and separating desired diastereoisomers by controlled crystallisation steps; narrow particle size distribution | TSHR, GYPA, GLRB | TSHR 1/4885PTGDR2 843/4885SLC6A3 2627/4885 |
| US-20090062372-A1 | Glycopyrronium Salts and Their Therapeutic Use | TPO, THRB, GYPA | TSHR 5/4885PTGDR2 1076/4885SLC6A3 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.